Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia.

Diana S. Woodruff-Pak, Thomas J. Gould

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Nicotinic acetylcholine receptors (nAChRs) play a role in a variety of diseases of the central nervous system including Alzheimer's disease (AD) and schizophrenia. There is great interest in evaluating disease-related nA ChR changes, and pharmacological treatment of nAChR deficits is a promising therapy. In AD, 7 nAChRs remain relatively stable, contrasting to 4 2 nAChRs that are lost in substantial numbers. -amyloid, a major neuropathology in AD, blocks 4 2 and 7 nAChRs. Agonists selective to 7nAChRs are neuroprotective against--amyloid. Paradoxically, 7nAChRs may function as receptors for -amyloid. These results indicate 7 nAChR antagonists may be appropriate therapy in AD. In schizophrenia, 7 nAChRs are significantly reduced in hippocampus and neocortex. The exceptionally high rate of smoking in schizophrenics is likely a form of self-medication. Therapy with 7 nAChR agonists relieves some schizophrenic symptoms. Despite disparities in etiology and symptomatology, AD and schizophrenia share a target for therapeutic intervention--7 nAChRs.

Original languageEnglish (US)
Pages (from-to)5-20
Number of pages16
JournalBehavioral and Cognitive Neuroscience Reviews
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2002

Fingerprint

Nicotinic Receptors
Schizophrenia
Alzheimer Disease
Amyloid
Therapeutics
Self Medication
Central Nervous System Diseases
Neocortex
Hippocampus
Smoking
Pharmacology

All Science Journal Classification (ASJC) codes

  • Cognitive Neuroscience
  • Behavioral Neuroscience

Cite this

@article{785405d0483e4aebbe3f66fbb68904d3,
title = "Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia.",
abstract = "Nicotinic acetylcholine receptors (nAChRs) play a role in a variety of diseases of the central nervous system including Alzheimer's disease (AD) and schizophrenia. There is great interest in evaluating disease-related nA ChR changes, and pharmacological treatment of nAChR deficits is a promising therapy. In AD, 7 nAChRs remain relatively stable, contrasting to 4 2 nAChRs that are lost in substantial numbers. -amyloid, a major neuropathology in AD, blocks 4 2 and 7 nAChRs. Agonists selective to 7nAChRs are neuroprotective against--amyloid. Paradoxically, 7nAChRs may function as receptors for -amyloid. These results indicate 7 nAChR antagonists may be appropriate therapy in AD. In schizophrenia, 7 nAChRs are significantly reduced in hippocampus and neocortex. The exceptionally high rate of smoking in schizophrenics is likely a form of self-medication. Therapy with 7 nAChR agonists relieves some schizophrenic symptoms. Despite disparities in etiology and symptomatology, AD and schizophrenia share a target for therapeutic intervention--7 nAChRs.",
author = "Woodruff-Pak, {Diana S.} and Gould, {Thomas J.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1177/1534582302001001002",
language = "English (US)",
volume = "1",
pages = "5--20",
journal = "Behavioral and Cognitive Neuroscience Reviews",
issn = "1534-5823",
publisher = "SAGE Publications Inc.",
number = "1",

}

Neuronal nicotinic acetylcholine receptors : involvement in Alzheimer's disease and schizophrenia. / Woodruff-Pak, Diana S.; Gould, Thomas J.

In: Behavioral and Cognitive Neuroscience Reviews, Vol. 1, No. 1, 01.01.2002, p. 5-20.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Neuronal nicotinic acetylcholine receptors

T2 - involvement in Alzheimer's disease and schizophrenia.

AU - Woodruff-Pak, Diana S.

AU - Gould, Thomas J.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Nicotinic acetylcholine receptors (nAChRs) play a role in a variety of diseases of the central nervous system including Alzheimer's disease (AD) and schizophrenia. There is great interest in evaluating disease-related nA ChR changes, and pharmacological treatment of nAChR deficits is a promising therapy. In AD, 7 nAChRs remain relatively stable, contrasting to 4 2 nAChRs that are lost in substantial numbers. -amyloid, a major neuropathology in AD, blocks 4 2 and 7 nAChRs. Agonists selective to 7nAChRs are neuroprotective against--amyloid. Paradoxically, 7nAChRs may function as receptors for -amyloid. These results indicate 7 nAChR antagonists may be appropriate therapy in AD. In schizophrenia, 7 nAChRs are significantly reduced in hippocampus and neocortex. The exceptionally high rate of smoking in schizophrenics is likely a form of self-medication. Therapy with 7 nAChR agonists relieves some schizophrenic symptoms. Despite disparities in etiology and symptomatology, AD and schizophrenia share a target for therapeutic intervention--7 nAChRs.

AB - Nicotinic acetylcholine receptors (nAChRs) play a role in a variety of diseases of the central nervous system including Alzheimer's disease (AD) and schizophrenia. There is great interest in evaluating disease-related nA ChR changes, and pharmacological treatment of nAChR deficits is a promising therapy. In AD, 7 nAChRs remain relatively stable, contrasting to 4 2 nAChRs that are lost in substantial numbers. -amyloid, a major neuropathology in AD, blocks 4 2 and 7 nAChRs. Agonists selective to 7nAChRs are neuroprotective against--amyloid. Paradoxically, 7nAChRs may function as receptors for -amyloid. These results indicate 7 nAChR antagonists may be appropriate therapy in AD. In schizophrenia, 7 nAChRs are significantly reduced in hippocampus and neocortex. The exceptionally high rate of smoking in schizophrenics is likely a form of self-medication. Therapy with 7 nAChR agonists relieves some schizophrenic symptoms. Despite disparities in etiology and symptomatology, AD and schizophrenia share a target for therapeutic intervention--7 nAChRs.

UR - http://www.scopus.com/inward/record.url?scp=0345552469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345552469&partnerID=8YFLogxK

U2 - 10.1177/1534582302001001002

DO - 10.1177/1534582302001001002

M3 - Review article

C2 - 17715584

AN - SCOPUS:0345552469

VL - 1

SP - 5

EP - 20

JO - Behavioral and Cognitive Neuroscience Reviews

JF - Behavioral and Cognitive Neuroscience Reviews

SN - 1534-5823

IS - 1

ER -